In exercise of the powers conferred by paragraphs 5 11 and 15 of the Drugs Prices Control

jftLVªh laö Mhö ,yö&33004@99 REGD. NO. D. L.-33004/99 vlk/kj.k EXTRAORDINARY Hkkx II—[k.M 3—mi&[k.M (ii) PART II—Section 3—Sub-section (ii) izkf/dkj ls izdkf'kr PUBLISHED BY AUTHORITY la- 1696] ubZ fnYyh] 'kqØokj] ebZ 31] 2019@T;s"B 10] 1941 No. 1696] NEW DELHI, FRIDAY, MAY 31, 2019/JYAISTHA 10, 1941 jlk;u vkSj moZjd ea=ky; ¼vkS"k/k foHkkx½ ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ vkns’k ubZ fnYyh] 31 ebZ] 2019 dk-vk- 1894¼v½-—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼6½ eas fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½] ¼4½] vkSj ¼5½ eas rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk] bdkbZ ¼;wfuV½ vkSj fofuekZrk vkSj foi.ku dEifu;ksa ds uke lfgr LraHk ¼2½ esa dh rRLFkkuh izfof"V esa ls izR;sd dh] oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i esa fu;r djrh gSA lkj.kh Ø- vuqlwfpr fofufeZfr izcyrk bdkbZ fofuekZrk vkSj foi.ku [kqnjk la- dk uke@czkaM dk daiuh ewY; ¼#-½ uke (1) (2) (3) (4) (5) (6) 1. vYQk fyiksbd $ izR;sd lkWQ~V tsysfVudSIlwy esa% eSllZ vksykbo 15.66 feFkkbydksckyfeu $ vYQk fyiksbd ,flM ;w,lih 200 fexzk- gsYFkds;j@eSllZ buksflVksy ;w,lih $ feFkkbydksckyfeu 1500 fexzk-] tk;Ml gsYFkds;j fy- QkWfyd ,flM $ buksflVksy ;w,lih ,u,Q 100 fexzk-] csUQksVh;kekbu QkWfyd ,flM vkbZih 1-5 fexzk-] 1 dSIlwy $Øksfe;e csUQksVh;kekbu 150 fexzk-] ikWfyfduksfVusV $ Øksfe;e ikWfyfduksfVusV 200 ,elhth ] ikbfjMksDlhu ikbfjMksDlhu gkbMªksDyksjkbM vkbZih 3 gkbMªksDyksjkbM fexzk- dSIlwy 2726 GI/2019 (1)2 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 2. Okksojku 1 fefy- ,D;w izR;sd 1 fefy- Xykl ,eikWy esa% eSllZ fufru ykbQ 21.92 batsD’ku fMDyksQsukd lksfM;e vkbZih 75 fexzk] ij lkbalht@eSllZ fefy-iSd okVj QkWj batsD’ku uksokVhZt bafM;k fy- 3. fMDyksQsukd $ izR;sd gkMZ tsysfVu dSIlwy esa% eSllZ ,dEl MªXl ,aM 12.61 fFk;ksdksylhdkslkbM fMDyksQsukd lksfM;e vkbZih 50 fexzk- QkekZL;wfVdYl fy- dSIlwy ¼,afVªd fyfir xksyh esa½] 1 dSIlwy @eSllZ uksokVhZt bafM;k fFk;ksdksylhdkslkbM 4 fexzk- fy- 4. fMDyksQsukd $ izR;sd gkMZ tsysfVu dSIlwy esa% eSllZ ,dEl MªXl ,aM 18.91 fFk;ksdksylhdkslkbM fMDyksQsukd lksfM;e vkbZih 50 fexzk- QkekZL;wfVdYl fy- dSIlwy ¼,afVªd fyfir xksyh esa½] 1 dSIlwy @eSllZ uksokVhZt bafM;k fFk;ksdksylhdkslkbM 8 fexzk- fy- 5. ,eksfDlflfyu $ izR;sd fQYe fyfir xksyh esa% 30.75 eSllZ fFkvksu Dykoqykfud ,flM ,eksfDlflfyu VªhgkbMªsV vkbZih ds QkekZL;wfVdYl fy- xksyh ¼;wuheksDl lhoh cjkcj ,eksfDlflfyu 875 fexzk-] 1 xksyh 1000½ iksVsf’k;e DykoqykusV fMyqfVM vkbZih Q@ kee kSl ZL;l wfZ Ve dSd Yf le y fyu - ds cjkcj Dykoqykfud ,flM 125 fexzk- 6. XyhesfijkbM $ izR;sd vfyfir fcys;MZ xksyh esa% 11.80 eSllZ fFkvksu esVQksfeZu $ XyhesfijkbM vkbZih 2 fexzk-] oksXyhcksl xksyh esVQksfeZu gkbMªksDyksjkbM vkbZih 500 1 xksyh QkekZL;wfVdYl fy- @eSllZ buMksdks fexzk- ¼lLVsaM fjfyt QkWeZ esa½] jsehMht fy- oksXyhcksl vkbZih 0-2 fexzk- 7. ,fjFkzksiksbfVu $ izR;sd 1-0 fefy- esa% 6490.00 g~;qeu ,Ycqfeu $ ,fjFkzksiksbfVu duluVªsM lksyq’ku vkbZih lksfM;e DyksjkbM $ 40000 vkbZ;w] lksfM;e QkWLQsV $ g~;qeu ,Ycqfeu vkbZih 2-50 fexzk- lksfM;e fMgkbMªkstu ij eSllZ lsje baLVhVwV QksLQsV eksuksgkbMªsV lksfM;e DyksjkbM vkbZih 7-80 fexzk- okby vkWQ bafM;k izk- fy- lksfM;e QkWLQsV vkbZih 2-20 fexzk- batsD’ku ¼jsiksbfVu 40000½ lksfM;e fMgkbMªkstu QksLQsV eksuksgkbMªsV ch-ih- 96 fexzk- okVj QkWj batsD’ku vkbZih D;w-,l- 8. ,EyksfMfiu $ izR;sd fQYe fyfir fcys;MZ xksyh esa% 5.51 eSllZ I;ksj ,aM D;ksj esVksizksyksy xksyh ,EyksfMfiu fclkbysV ds cjkcj gsYFkds;j izk- fy-@eSllZ ¼,EykslsQ ,eVh 25 ,EyksfMfiu 5 fexzk-]esVksizksyksy lqLlhusV 1 xksyh fexzk-½ 23-75 fexzk- ds cjkcj esVksizksyksy ,fjLVks iQ zkk -e fk yZL; - wfVdYl VkjVªsV 25 fexzk- ¼izksykWxM fjfyt esa½ 9. jcsizktksy $ izR;sd dSIlwy esa% 8.24 MkseisfjMksu dSIlwy jcsizktksy lksfM;e vkbZih 20 fexzk- ¼buLVsd Mh dSIlwy½ ¼,afVªd fyfir isysVl esa½ 1 dSIlwy eSl gsYl FZ kdbu s;o jsu fV yh; - k MkseisfjMksu vkbZih 30 fexzk- ¼lLVsaM fjfyt iSysVl esa½ 10. isaVksizktksy $ izR;sd gkMZ tsysfVu dSIlwy esa% 8.007 MkseisfjMksu dSIlwy isaVksizktksy lksfM;e vkbZih ¼isaVksizktksy ¼MksesykWx ih dSIlwy½ lksfM;e lslD;wbZgkbMªsV½ ds cjkcj eSllZ buosuVh;k isaVksizktksy 40 fexzk- ¼xsLVªks&jsflLVsaV 1 dSIlwy gsYFkds;j fy- isysVl½ MkseisfjMksu vkbZih 30 fexzk- ¼izksyksx fjfyt iSysVl esa½ 11. esVQksfeZu $ izR;sd vfyfir fcys;MZ xksyh esa% eSllZ buosuVh;k 6.76 oksXyhcksl xksyh esVQksfeZu gkbMªksDyksjkbM vkbZih 500 gsYFkds;j fy- ¼izksXywVªksy oh 0-2½ fexzk- ¼lLVsaM fjfyt QkWeZ esa½ 1 xksyh oksXyhcksl vkbZih 0-2 fexzk- 12. esVQksfeZu $ izR;sd vfyfir fcys;MZ xksyh esa% eSllZ buosuVh;k 8.56 oksXyhcksl xksyh esVQksfeZu gkbMªksDyksjkbM vkbZih 500 gsYFkds;j fy- ¼izksXywVªksy oh 0-3½ fexzk- ¼lLVsaM fjfyt QkWeZ esa½ 1 xksyh oksXyhcksl vkbZih 0-3 fexzk-¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 3 13. esVQksfeZu $ izR;sd vfyfir fcys;MZ xksyh esa% eSllZ buosuVh;k 5.13 XyhesfijkbM xksyh esVQksfeZu gkbMªksDyksjkbM vkbZih 500 gsYFkds;j fy-. ¼izksXywVªksy th1½ fexzk- ¼izksykWxM fjfyt QkWeZ esa½ 1 xksyh XyhesfijkbM vkbZih 1 fexzk- 14. esVQksfeZu $ izR;sd vfyfir fcys;MZ xksyh esa% eSllZ buosuVh;k 6.76 XyhesfijkbM xksyh esVQksfeZu gkbMªksDyksjkbM vkbZih 500 gsYFkds;j fy- ¼izksXywVªksy th2½ fexzk- ¼izksykWxM fjfyt QkWeZ esa½ 1 xksyh XyhesfijkbM vkbZih 2 fexzk- 15. esVQksfeZu $ izR;sd vfyfir fcys;MZ xksyh esa% eSllZ buosuVh;k 6.47 XyhesfijkbM esVQksfeZu gkbMªksDyksjkbM vkbZih 1000 gsYFkds;j fy- ¼izksXywVªksy th1 QksVZ½ fexzk- ¼izksykWxM fjfyt QkWeZ esa½ 1 xksyh XyhesfijkbM vkbZih 1 fexzk- 16. esVQksfeZu $ izR;sd vfyfir fcys;MZ xksyh esa% eSllZ buosuVh;k 8.75 XyhesfijkbM esVQksfeZu gkbMªksDyksjkbM vkbZih 1000 gsYFkds;j fy- ¼izksXywVªksy th2 QksVZ½ fexzk- ¼izksykWxM fjfyt QkWeZ esa½ 1 xksyh XyhesfijkbM vkbZih 2 fexzk- 17. iSaVksizktksy lksfM;e izR;sd gkMZ tsysfVu dSIlwy esa% eSllZ fo|k’kk 16.72 $ bVksizkbM iSaVksizktksy lksfM;e vkbZih ds cjkcj QkekZL;wfVdYl@eSllZ gkbMªksDyksjkbM iSaVksizktksy 40 fexzk- ¼,afVªd fyfir eSdfeyu QkekZL;wfVdYl dSIlwy isysVl esa½] 1 dSIlwy fy- ¼isutks&vkbZVh½ bVksizkbM gkbMªksDyksjkbM 150 fexzk- ¼lLVsaM fjfyt isysVl½ 18. ,VksjokLVkVhu xksyh izR;sd fQYe fyfir xksyh esa% 27.54 ¼VkWjoklksu &80½ ,VksjokLVkVhu dSfY’k;e ds cjkcj 1 xksyh QekZLe ;Sl wfVl dZ ; Ylwuh l iu zk- fy- ,VksjokLVkVhu 80 fexzk- uksV % ¼d½ mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku ds fofuekZrk vFkkZr tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼;w½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsA ¼[k½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (6) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM+ ldrs gSaA ¼x½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ V esa vf/klwpuk dh rkjh[k ls ,d ewY; lwph ,uihih, dks vkbZihMh,e,l ds ek/;e ls tkjh djsa rFkk mldh dkiWh jkT; vkS"kf/k fu;a=dksa vkSj fofuekZrk forjdksa dks tkjh djsaA ¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izR;sd QqVdj foØsrk vkSj forjd fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjckj dks bl izdkj fd;k tk jgk gS fd mlls ijke’kZ ds bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn`’; Hkkx ij dher lwph vkSj iwjd lwph] ;fn dksbZ gks] dks laiznf’kZr djsxkA ¼M-½ mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr fuekZrk@foi.ku ds fy, ykxw gS tSlk fd mUgksaus vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds rgr vuqc) ewY; fu/kkZj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k Fkk vkSj ljdkj }kjk fu/kkZfjr lHkh ykxw oS/kkfud vko';drkvksa dh iwfrZ ds v/khu izklafxd fof/k;ksa@fu;eksa ds vUrxZr tSlk fd dsUnzh;@jkT; ykblsflax vkWFkksfjVh ds l{ke izkf/kdkjh }kjk esU;wQsDpfjax ykblsal eatwjh ds rgr lacaf/kr fofufeZr fuekZrk@foi.ku dEifu;ka tks vuqikyu djrh gSA ¼p½ fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA4 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ¼N½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZfr;ksa ds iSdksa dh [kqnjk ewY; fu;r gksus ds ifj.kkeLo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxsA [dka- la- 199@67/2019@,Q@Qk- la- 8¼67½@2019@Mhih@,uihih,&fMoh--II] izlsuthr nkl] lgk;d funs'kd MINISTRY OF CHEMICALS AND FERTILIZERS (Department of Pharmaceuticals) (NATIONAL PHARMACEUTICAL PRICING AUTHORITY) ORDER New Delhi, the 31st May, 2019 S.O. 1894(E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof; Table Sl. Name of the Strength Unit Manufacturer & Retail No. Formulation / Brand Marketing Company Price Name (Rs.) (1) (2) (3) (4) (5) (6) 1. Alpha Lipoic + Each soft gelatine capsule contains: M/s Olive Healthcare / 15.66 Methylcobalamin + Alpha Lipoic Acid USP 200 mg, M/s Zydus Healthcare Inositol USP + Folic Methylcobalamin 1500 mcg, Limited Acid + Benfotiamine + Inositol USP NF 100 mg, Folic Acid IP 1 Chromium 1.5mg, Benfotiamine 150 mg, Chromium Capsule Polynicotinate + Polynicotinate 200 mcg, Pyridoxine Pyridoxine Hydrochloride IP 3 mg Hydrochloride Capsule 2. Voveran 1ml AQ Each 1ml glass ampoule contains: 21.92 Per 1ml M/s Nitin Life Sciences / Injection Diclofenac Sodium IP 75mg, Pack M/s Novartis India Limited Water for Injection 3. Diclofenac + Each Hard Gelatin capsule contains: 12.61 M/s Akums Drugs & Thiocolchicoside Diclofenac Sodium IP 50mg (As Enteric 1 Pharmaceuticals Ltd. / M/s Capsule coated tablet) Capsule Novartis India Limited Thiocolchicoside 4mg 4. Diclofenac + Each Hard Gelatin capsule contains: 18.91 M/s Akums Drugs & Thiocolchicoside Diclofenac Sodium IP 50mg (As Enteric 1 Pharmaceuticals Ltd. / M/s Capsule coated tablet) Capsule Novartis India Limited Thiocolchicoside 8mg 5. Amoxycillin + Each film coated tablet contains: 30.75 M/s Theon Clavulanic Acid Tablet Amoxycillin Trihydrate IP eq. to Pharmaceuticals Ltd. / M/s (UNIMOX CV 1000) Amoxycillin 875mg, 1 Tablet Macmillon Potassium Clavulanate Diluted IP eq. to Pharmaceuticals Limited Clavulanic Acid 125mg 6. Glimepiride + Each uncoated bilayered tablet contains: 11.80 M/s Theon Metformin + Voglibose Glimepiride IP 2mg, Pharmaceuticals Limited / Tablet Metformin Hydrochloride IP 500mg (As 1 Tablet M/s Indoco Remedies Sustained Release form), Limited Voglibose IP 0.2mg¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 5 7. Erythropoietin + Each 1.0ml contains: 6490.00 Human Albumin + Erythropoietin Concentrated Solution IP Sodium Chloride + 40000IU Sodium Phosphate + Human Albumin IP 2.50mg, M/s Serum Institute of Sodium Dihydrogen Sodium Chloride IP 7.80mg, Per Vial India Pvt. Ltd. Phosphate Sodium Phosphate IP 2.20mg Monohydrate Injection Sodium Dihydrogen Phosphate (Repoitin 40000) Monohydrate B. P. 0.96mg Water for Injection IP q.s. 8. Amlodipine + Each film coated bilayered Tablet contains: 5.51 Metoprolol Tablet Amlodipine Besilate eq. to Amlodipine M/s Pure & Cure (Amlosafe MT 25mg) 5mg, Healthcare Pvt. Ltd. / M/s 1 Tablet Metoprolol Succinate 23.75mg eq. to Aristo Pharmaceuticals Metoprolol Tartrate 25mg (As Prolonged Pvt. Ltd. Release) 9. Rabeprazole + Each capsule contains: 8.24 Domperidone Capsule Rabeprazole Sodium IP 20mg (as enteric 1 M/s Inventia Healthcare (Instek D Capsule) coated pellets), Capsule Limited Domperidone IP 30mg (as sustained release pellets) 10. Pantoprazole + Each hard gelatin capsule contains: 8.007 Domperidone Capsule Pantoprazole Sodium IP (as Pantoprazole (Domelong P Capsule) Sodium Sesquihydrate) eq. to Pantoprazole 1 M/s Inventia Healthcare 40mg (as Gastro-resistant pellets) Capsule Limited Domperidone IP 30mg (as Prolonged release pellets) 11. Metformin + Voglibose Each uncoated bilayered tablet contains: M/s Inventia Healthcare 6.76 Tablet (Proglutrol V Metformin Hydrochloride IP 500mg (in Pvt. Ltd. 1 Tablet 0.2) Sustained release form), Voglibose IP 0.2mg 12. Metformin + Voglibose Each uncoated bilayered tablet contains: M/s Inventia Healthcare 8.56 Tablet (Proglutrol V Metformin Hydrochloride IP 500mg (in Pvt. Ltd. 1 Tablet 0.3) Sustained release form), Voglibose IP 0.3mg 13. Metformin + Each uncoated bilayered tablet contains: M/s Inventia Healthcare 5.13 Glimepiride Tablet Metformin Hydrochloride IP 500mg (in Pvt. Ltd. 1 Tablet (Proglutrol G1) prolonged release form), Glimepiride IP 1mg 14. Metformin + Each uncoated bilayered tablet contains: M/s Inventia Healthcare 6.76 Glimepiride Tablet Metformin Hydrochloride IP 500mg (in Pvt. Ltd. 1 Tablet (Proglutrol G2) prolonged release form), Glimepiride IP 2mg 15. Metformin + Each uncoated bilayered tablet contains: M/s Inventia Healthcare 6.47 Glimepiride Tablet Metformin Hydrochloride IP 1000mg (in Pvt. Ltd. 1 Tablet (Proglutrol G1 Forte) prolonged release form), Glimepiride IP 1mg 16. Metformin + Each uncoated bilayered tablet contains: M/s Inventia Healthcare 8.75 Glimepiride Tablet Metformin Hydrochloride IP 1000mg (in Pvt. Ltd. 1 Tablet (Proglutrol G2 Forte) prolonged release form), Glimepiride IP 2mg 17. Pantoprazole Sodium + Each hard gelatine capsules contains: M/s Vidhyasha 16.72 Itopride Hydrochloride Pantoprazole Sodium IP eq. to Pantoprazole Pharmaceuticals / M/s 1 Capsules (PANZO-IT) 40mg (as enteric coated pellets), Macmillon Capsule Itopride Hydrochloride 150mg (as sustained Pharmaceuticals Limited release pellets) 18. Atorvastatin Tablet Each film coated tablet contains: 27.54 M/s Unison (TORVASON -80) Atorvastatin Calcium IP eq. to Atorvastatin 1 Tablet Pharmaceuticals Pvt. Ltd. 80mg6 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Note: (a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove. (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table. (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies. (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/199/67/2019/F /F. No. 8(67)/2019/D.P./NPPA-Div.-II] PRASENJIT DAS, Asst. Director Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064 and Published by the Controller of Publications, Delhi-110054.